Study |
Study population |
Characteristics |
N |
Design |
Main findings * |
Dore et al. 2005 [59] |
Systemic RV (TGA) |
Majority NYHA I
RVEF 42% |
29 |
Multicenter RCT crossover design
Losartan vs. placebo for 15 weeks |
No difference in peak VO2, exercise duration or NT-proBNP levels. |
Lester et al.
2001 [60] |
D-TGA (atrial baffle)
|
Age > 13 yrs
NYHA < IV
RVEF 48% |
7 |
RCT, crossover design. Losartan vs. placebo for 8 weeks |
Beneficial effect: ↑exercise time by 18%, ↓ regurgitant volume by 63.5%, ↑ RVEF 6%‡ |
Robinson et al. 2002 [61] |
D-TGA (atrial baffle) |
NYHA I
Age 7 to 21 yrs
CI 2.2 L/min/m2 |
8 |
Single arm prospective study
Enalapril for 1 year |
No difference in exercise duration, peak VO2 or cardiac index |
Therrien et al. 2008 [62] |
D-TGA (atrial baffle) |
Mainly NYHA class I
Age > 18 yrs
RVEF 44% |
17
|
Multicenter RCT
Ramipril vs. placebo for 1 year |
No difference in RVEF, RV volume or peak VO2 |
Hechter et al. 2001 [63] |
D-TGA (atrial baffle) |
Age > 26 yrs
RVEF 47% |
26 |
Retrospective study
ACE-I from 6 to 126 months |
No difference in peak VO2, exercise duration |
